Bristol Myers Squibb (BMY) Net Cash Flow (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Net Cash Flow for 18 consecutive years, with -$851.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 152.92% year-over-year to -$851.0 million in Q2 2026; TTM through Jun 2026 was -$3.8 billion, a 161.9% decrease from a year earlier, with the FY2025 full-year figure at -$324.0 million, up 68.7% from the prior year.
• Net Cash Flow was -$851.0 million for Q2 2026 at Bristol Myers Squibb, down from -$587.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $3.9 billion in Q4 2023 and troughed at -$5.5 billion in Q4 2025.
• A 5-year average of -$311.4 million and a median of -$601.0 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 2768.97% in 2022 and jumped 285.59% in 2024, its largest moves.
• Over 5 years, Net Cash Flow stood at $1.3 billion in 2022, then jumped by 204.24% to $3.9 billion in 2023, then sank by 32.84% to $2.6 billion in 2024, then slumped by 311.96% to -$5.5 billion in 2025, then surged by 84.56% to -$851.0 million in 2026.
• The last three Net Cash Flow figures came in at -$851.0 million (Q2 2026), -$587.0 million (Q1 2026), and -$5.5 billion (Q4 2025), per Business Quant data.